Expertise

Our experience encompasses all areas of biosafety and biosecurity be it in industry, academia, authorities or open space.

E1 E2 E3 E4 E5 E6

Environmental risk assessment of gene therapy
products and recombinant vaccines

  • Evaluation of new techniques and environmental risk assessment for research, clinical trials, field releases or market application

  • Advice on biosafety and prevention of misuse in biological science as member of the Forum for Genetic Research of the Swiss Academy of Sciences 2006-2020

  • Advice on environmental risk assessment reports for the potential application of the placing on the market of genetically modified live viral vaccines since 2013. Examples from industry upon request

  • Design of environmental risk assessment reports for the application of the placing on the market of genetically modified cell therapy since 2013. Examples from industry upon request

  • Design of environmental risk assessment reports for the application of clinical trials and the placing on the market of ATMPs and recombinant vaccines, since 2006. Examples from industry upon request

  • Evaluation of safe application of ATMPs and recombinant vaccines regarding environmental safety and safety for medicinal personnel and contact persons, since 2001. Examples from industry upon request

Nobel Prize Summit OUR PLANET OUR FUTURE Urgent Call for Action

Mai 21 2021
The 2021 Nobel Prize Summit of April 2021, has resulted in an Urgent Call for Action concluding that global sustainability offers the only viable path forward in the Anthropocene epoch.

1st ABSA Biosecurity Conference, lessons learnt

April 26 2021
The highly diverse program of the first biosecurity conference of ABSA international highlights past experiences and future prospects in biosecurity

COVID-19 and the UN Sustainable Development Goals

April 19 2021
„Biosafety: gatekeeper for sustainability in biotechnology?“ (https://sdgs.un.org/goals)
Go to Blog